Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M154,681Revenue $M12,927Net Margin (%)31.9Altman Z-Score17.5
Enterprise Value $M149,621EPS $1.5Operating Margin %40.5Piotroski F-Score8
P/E(ttm)35.0Beneish M-Score-2.4Pre-tax Margin (%)40.9Higher ROA y-yY
Price/Book32.510-y EBITDA Growth Rate %18.8Quick Ratio0.7Cash flow > EarningsY
Price/Sales11.25-y EBITDA Growth Rate %19.6Current Ratio1.0Lower Leverage y-yY
Price/Free Cash Flow38.3y-y EBITDA Growth Rate %21.2ROA % (ttm)42.4Higher Current Ratio y-yN
Dividend Yield %1.3PEG1.8ROE % (ttm)82.8Less Shares Outstanding y-yY
Payout Ratio %44.0Shares Outstanding M2,650ROIC % (ttm)110Gross Margin Increase y-yY

Gurus Latest Trades with NVO

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NVOKen Fisher 2015-06-30 Reduce-0.04%$53.39 - $58.02
($56.17)
$ 58.374%Reduce 2.88%12,295,864
NVOKen Fisher 2015-03-31 Reduce-0.03%$41.9 - $54.68
($46.05)
$ 58.3727%Reduce 2.91%12,660,235
NVORuane Cunniff 2015-03-31 Reduce$41.9 - $54.68
($46.05)
$ 58.3727%Reduce 0.17%82,050
NVOMario Gabelli 2015-03-31 Reduce$41.9 - $54.68
($46.05)
$ 58.3727%Reduce 0.30%6,700
NVORuane Cunniff 2014-09-30 Reduce-0.02%$43.9 - $49.03
($46)
$ 58.3727%Reduce 52.87%75,642
NVORuane Cunniff 2014-06-30 Reduce-0.02%$42.28 - $46.52
($44.12)
$ 58.3732%Reduce 33.85%160,492
NVORuane Cunniff 2014-03-31 Reduce-0.01%$36.722 - $48.23
($42.37)
$ 58.3738%Reduce 21.98%242,630
NVORuane Cunniff 2013-12-31 Add0.02%$32.72 - $36.952
($34.87)
$ 58.3767%Add 58.71%310,970
NVOTom Gayner 2013-12-31 Reduce$32.72 - $36.952
($34.87)
$ 58.3767%Reduce 0.23%1,106,000
NVOKen Fisher 2013-12-31 Add$32.72 - $36.952
($34.87)
$ 58.3767%Add 0.29%13,553,935
NVOTom Gayner 2013-09-30 Reduce-0.02%$31.67 - $35.236
($33.64)
$ 58.3774%Reduce 1.51%1,108,500
NVOMario Gabelli 2013-09-30 Reduce$31.67 - $35.236
($33.64)
$ 58.3774%Reduce 0.58%8,520
NVORuane Cunniff 2013-09-30 Add$31.67 - $35.236
($33.64)
$ 58.3774%Add 13.12%195,930
NVOKen Fisher 2013-09-30 Add$31.67 - $35.236
($33.64)
$ 58.3774%Add 0.43%13,514,205
NVORuane Cunniff 2013-06-30 Buy 0.04%$30.11 - $35.326
($33.29)
$ 58.3775%New holding173,200
NVOKen Fisher 2013-06-30 Add0.01%$30.11 - $35.326
($33.29)
$ 58.3775%Add 0.92%13,456,455
NVOTom Gayner 2013-06-30 Reduce-0.01%$30.11 - $35.326
($33.29)
$ 58.3775%Reduce 0.57%1,125,500
NVOMario Gabelli 2013-06-30 Reduce$30.11 - $35.326
($33.29)
$ 58.3775%Reduce 1.15%8,570
NVOTom Gayner 2013-03-31 Reduce-0.01%$32.24 - $38.86
($34.97)
$ 58.3767%Reduce 0.40%1,132,000
NVOMario Gabelli 2013-03-31 Reduce$32.24 - $38.86
($34.97)
$ 58.3767%Reduce 60.32%8,670
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NVO is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


NVO: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Quarterly/Annual Reports about NVO:

    News about NVO:

    Articles On GuruFocus.com
    Nintai Returns: Q2 2015 Jul 01 2015 
    Leith Wheeler Investment Funds First Quarter 2015 Review Jun 15 2015 
    Jim Simons' Top 3 Positions and One That Doubled Return Jun 10 2015 
    Weekly 52-Week Highs Highlight: ALTR, AIG, LUX, NVO, EXPE May 03 2015 
    MannKind Looks Good For Long Term Investors Apr 29 2015 
    Additional Changes to the Nintai Portfolio Apr 08 2015 
    Probability and Magnitude in Investing Apr 02 2015 
    Nintai Returns: Q1 2015 Apr 01 2015 
    These High-Quality European Dividend Payers Could Benefit From A Rising Dollar Mar 18 2015 
    To Reinvest or Not Reinvest: That is the Question Feb 19 2015 

    More From Other Websites
    Business Highlights Jul 28 2015
    AbbVie: Beware the Biosimilars? Jul 24 2015
    Appointment Notice - Novo Nordisk Canada Inc. Jul 24 2015
    Appointment Notice - Novo Nordisk Canada Inc. Jul 24 2015
    Novo Nordisk says Flexpro PenMate gets FDA approval Jul 16 2015
    Novo Nordisk Up on Positive Results from Diabetes Study - Analyst Blog Jul 13 2015
    Novo Nordisk's new GLP-1 diabetes drug hits goal in trial Jul 10 2015
    Novo Nordisk Halts Sale of Tresiba Insulin in Germany Over Pricing Dispute Jul 02 2015
    The Greek debt crisis turned these European stocks into even better buys Jul 01 2015
    Status regarding Novo Nordisk's holding of its own shares (30 June 2015) Jul 01 2015
    Levemir® receives positive CHMP opinion for extended use in children as young as one year old Jun 26 2015
    Conquering Hemophilia: Novo Nordisk Reports Encouraging Data From Phase III Trial Of NovoEight Jun 25 2015
    Cramer: Getting down to BAX's Biz Jun 24 2015
    In a phase 3 trial, NovoEight® provided long-term efficacy and safety in the prophylaxis and... Jun 24 2015
    Fase 3-studie med NovoEight® viser langvarig effekt og sikkerhed ved forebyggelse og behandling af... Jun 24 2015
    Novo Nordisk A/S - Aktietilbagekøbsprogram Jun 22 2015
    Novo Nordisk A/S - Share repurchase programme Jun 22 2015
    Novo Nordisk A/S upgraded by Morgan Stanley Jun 09 2015
    Novo Nordisk Reveals New Findings from Additional Studies - Analyst Blog Jun 08 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    Gintaras58
    ReplyGintaras58 - 1 year ago
    few excellent prducts to come soon
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK